Article Text

other Versions

PDF
Clinical significance of increased CD4+CD25-Foxp3+T cells in patients with new-onset systemic lupus erythematosus
  1. Biao Zhang (zhangbiao0902{at}yahoo.com.cn)
  1. Chinese Academy of Medical Science,Peking Union Medical College Hospital, China
    1. Xuan Zhang (zxpumch2003{at}yahoo.com.cn)
    1. Peking Union Medical College Hospital, China
      1. Fulin Tang
      1. Peking Union Medical College Hospital, China
        1. Liping Zhu
        1. Institution of Basic Medical Science,Chinese Academy of Medical Science, China
          1. Yin Liu
          1. Institution of Basic Medical Science,Chinese Academy of Medical Science, China
            1. Wanjun Chen
            1. Mucosal Immunology Unit, NIDCR, National Institutes of Health, United States
              1. Peter Lipsky
              1. Autoimmunity Branch, NIAMS, National Institutes of Health, United States

                Abstract

                Objective: To investigate the expressions of Foxp3 and CD25 on CD4+T cells from patients with new-onset systemic lupus erythematosus (SLE) and assess their clinical significance.

                Methods: Ten active (SLEDAI≥10) and eleven inactive (SLEDAI≤5) new-onset SLE patients as well as eleven healthy volunteers were enrolled. The expressions of CD25, Foxp3 and CD127 on CD4+ T cells were analyzed by flow cytometry. Proliferation assays were performed on isolated CD4+CD25+ and/or CD4+CD25- T cells.

                Results: There was no significant difference in number of CD4+CD25+Foxp3+T cells in subjects with either active or inactive SLE compared to normal controls (P>0.05). Moreover, suppressive capacity of CD4+CD25+T cells in new-onset lupus patients was not impaired as measured by the capacity to inhibit proliferation of CD4+CD25- T cells. Interestingly, CD4+CD25-Foxp3+T cells in new-onset lupus (2.97-10.94%) were significantly more frequent than in normal controls (1.01-3.62%) (P<0.01), and positively correlated with the titers of anti-dsDNA antibodies (P=0.029). Few of these cells expressed CD127. Treatment with glucocorticoids and cyclophosphamide reduced CD4+CD25-Foxp3+ T cells in eight of ten active patients.

                Conclusions: There was a significant increase in CD4+CD25-Foxp3+T cells in new-onset SLE patients that correlated with anti-dsDNA titers, whereas no alteration in either the percentage or function of CD4+CD25+Foxp3+T cells was observed.

                • CD127
                • CD25
                • CD4
                • Foxp3
                • SLE

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.